HomeCompareMCCRF vs MRK

MCCRF vs MRK: Dividend Comparison 2026

MCCRF yields 4.09% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $31.6K in total portfolio value
10 years
MCCRF
MCCRF
● Live price
4.09%
Share price
$1.71
Annual div
$0.07
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.1K
Annual income
$532.35
Full MCCRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — MCCRF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCCRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCCRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MCCRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCCRF
Annual income on $10K today (after 15% tax)
$347.95/yr
After 10yr DRIP, annual income (after tax)
$452.50/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,144.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCCRF + MRK for your $10,000?

MCCRF: 50%MRK: 50%
100% MRK50/50100% MCCRF
Portfolio after 10yr
$41.9K
Annual income
$5,323.07/yr
Blended yield
12.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MCCRF
No analyst data
Altman Z
3.2
Piotroski
4/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCCRF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCCRFMRK
Forward yield4.09%2.81%
Annual dividend / share$0.07$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$26.1K$57.7K
Annual income after 10y$532.35$10,113.78
Total dividends collected$4.7K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MCCRF vs MRK ($10,000, DRIP)

YearMCCRF PortfolioMCCRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,109$409.36$11,213$373.04$104.00MRK
2$12,312$425.02$12,667$512.06$355.00MRK
3$13,614$440.21$14,439$708.14$825.00MRK
4$15,022$454.92$16,640$988.16$1.6KMRK
5$16,543$469.13$19,432$1,394.07$2.9KMRK
6$18,183$482.82$23,057$1,992.90$4.9KMRK
7$19,952$495.99$27,889$2,894.79$7.9KMRK
8$21,858$508.64$34,518$4,286.29$12.7KMRK
9$23,908$520.76$43,912$6,494.35$20.0KMRK
10$26,114$532.35$57,714$10,113.78$31.6KMRK

MCCRF vs MRK: Complete Analysis 2026

MCCRFStock

McCoy Global Inc. provides equipment and technologies to support tubular running operations that enhance wellbore integrity and assist with collecting critical data for the energy industry primarily in Canada. It designs, produces, and distributes capital equipment to support wellbore integrity; and supports capital equipment sales through aftermarket products and services, such as technical support, consumables, and replacement parts. The company also offers data collection technologies used in rugged applications in the energy, construction, marine, and aerospace sectors; and repair, maintenance, and calibration services for the capital equipment and related competitor products; and corporation technology rental services. In addition, it provides hydraulic power tongs used to make-up and break-out casing, tubing, and drill-pipe; casing running tools; tubular running technologies; torque-turn monitoring and control software system; wireless data subs; mud handling equipment; bucking units for assembling couplings to casing in tubular manufacturing plants; diesel and electric hydraulic power units; roughnecks; load monitoring systems; portable aircraft digital scales; and winch control systems. The company offers aftermarket products and services, including dies and inserts for tubular make-up and handling equipment; and gauging services. It markets its products and services through direct sales, agents, re-sellers, and distributors primarily under the SmarTR, Virtual ThreadRep, SmartCRT, SmartFMS, CalCERT, DWCRT, weCATT, weVERIFY, winCATT, GRITFACE, CLINCHER, HYTOPS, CHROMEMASTER, LOCKJAW, weTORQ, Autofill, AutoValve, and SWSES brand names in the United States, Latin America, the Middle East, Africa, Europe, Russia, the Asia Pacific, and Canada. The company was formerly known as McCoy Corporation and changed its name to McCoy Global Inc. in July 2014. McCoy Global Inc. was founded in 1914 and is headquartered in Edmonton, Canada.

Full MCCRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MCCRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCCRF vs SCHDMCCRF vs JEPIMCCRF vs OMCCRF vs KOMCCRF vs MAINMCCRF vs JNJMCCRF vs ABBVMCCRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.